<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1206245414
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Akeega
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        NIRAPARIB,ABIRATERONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100,500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23027.20
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PATHEON" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PATHEON
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Janssen-Cilag International NV 
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        QL01XY
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Akeega is a medicine that contains two active substances: niraparib and abiraterone acetate, and works in two different ways.</p><p>&nbsp;</p><p>Akeega is used to treat adult men with prostate cancer who have changes in certain genes and whose prostate cancer has spread to other parts of the body and no longer responds to medical or surgical treatment that lowers testosterone (also called metastatic castration-resistant prostate cancer).</p><p>&nbsp;</p><p>Niraparib is a type of cancer medicine called a PARP inhibitor. PARP inhibitors block an enzyme called poly [adenosine diphosphate-ribose] polymerase (PARP). PARP helps cells repair damaged DNA. When PARP is blocked, cancer cells cannot repair their DNA, resulting in tumour cell death and helping to control the cancer.</p><p>&nbsp;</p><p>Abiraterone stops your body from making testosterone; this can slow the growth of prostate cancer.</p><p>&nbsp;</p><p>When you take this medicine, your doctor will also prescribe another medicine called prednisone or prednisolone. This is to lower your chances of getting high blood pressure, having too much water in your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Akeega:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to niraparib or abiraterone acetate or any of the other ingredients of this medicine - listed in section 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are a woman who is or can become pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have severe liver damage.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in combination with Ra-223 treatment (which is used to treat prostate cancer). This is because of a possible increase in the risk of bone fracture or death.</p><p>&nbsp;</p><p>Do not take this medicine if any of the above apply to you. If you are not sure, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor or pharmacist before or while taking this medicine if you have:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low blood cell counts. Signs and symptoms you need to look out for include fatigue, fever or infection, and abnormal bruising or bleeding. Akeega may also lower your blood cell counts. Your doctor will test your blood regularly throughout your treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure or heart failure or low blood potassium (low blood potassium may increase the risk of heart rhythm problems), have had other heart or blood vessel problems, have an irregular or rapid heart rate, shortness of breath, gained weight rapidly, or swelling in the feet, ankles, or legs. Your doctor will measure your blood pressure regularly throughout your treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headaches, vision changes, confusion, or seizure. These may be signs of a rare neurological side effect named posterior reversible encephalopathy syndrome (PRES) that has been associated with use of niraparib, an active ingredient of Akeega.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high fever, fatigue and other signs and symptoms of severe infection.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clots in the lungs or legs, or have had them in the past.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low or high levels of sugar in the blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness and/or muscle pain.</p><p>&nbsp;</p><p>If any of the above apply to you (or you are not sure), talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p>If you develop abnormal blood cell counts for a long period of time while taking Akeega, this may be a sign of more serious problems with the bone marrow such as &lsquo;myelodysplastic syndrome&rsquo; (MDS) or &lsquo;acute myeloid leukaemia&rsquo; (AML). Your doctor may want to test your bone marrow to check for these problems.</p><p>&nbsp;</p><p>Before taking Akeega, also talk to your doctor or pharmacist about:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the effect Akeega may have on your bones.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; taking prednisone or prednisolone (another medicine you must take with Akeega).</p><p>&nbsp;</p><p>If you are not sure if any of the above apply to you, talk to your doctor or pharmacist before taking this medicine.</p><p>&nbsp;</p><p><strong>Blood monitoring</strong></p><p>Akeega may affect your liver, but you may not notice any symptoms of liver problems. When you are taking this medicine, your doctor will therefore check your blood periodically to look for any effects on your liver.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>This medicine is not for use in children and adolescents. If Akeega is accidentally swallowed by a child or adolescent, take them to the hospital immediately and take this package leaflet with you to show to the emergency doctor.</p><p>&nbsp;</p><p><strong>Other medicines and Akeega</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. This is because Akeega can affect the way some other medicines work. Also, some other medicines can affect the way Akeega works.</p><p>&nbsp;</p><p>Treatment with medicines that stop the body from producing testosterone, may increase the risk of heart rhythm problems. Tell your doctor if you are receiving medicine:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to treat heart rhythm problems (e.g., quinidine, procainamide, amiodarone and sotalol);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; known to increase the risk of heart rhythm problems (e.g., methadone), used for pain relief and part of drug addiction detoxification; moxifloxacin, an antibiotic; antipsychotics, used for serious mental illnesses.</p><p>&nbsp;</p><p>Tell your doctor if you are taking any of the medicines listed above.</p><p>&nbsp;</p><p><strong>Akeega with food</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine must not be taken with food (see section&nbsp;3, &ldquo;Taking Akeega&rdquo;), as this may increase your risk of side effects.</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>Akeega is not for use in women.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine may cause harm to the unborn child if it is taken by women who are pregnant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Women who are pregnant or who may become pregnant should wear gloves if they need to touch or handle Akeega.</p><p>Contraception for men using Akeega</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are having sex with a woman who can become pregnant, use a condom and another effective birth control method. Use contraception during treatment and for 4 months after stopping. Talk to your doctor if you have any questions about contraception.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are having sex with a pregnant woman, use a condom to protect the unborn child.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>Taking Akeega may make you feel weak, unfocused, tired or dizzy. This may influence your ability to drive and use machines. Use caution when driving or using machines.</p><p>&nbsp;</p><p><strong>Akeega contains lactose and sodium</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Akeega contains lactose. If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; This medicine contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>How much to take</strong></p><p>The recommended starting dose is 200&nbsp;mg/1&nbsp;000 mg (two tablets) once a day.</p><p>&nbsp;</p><p><strong>Taking Akeega</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take this medicine by mouth.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Do not take Akeega with food.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take Akeega tablets as a single dose once daily on an empty stomach<strong> </strong><strong>at least one hour before or at least two hours after eating</strong> (see section 2, &ldquo;Akeega with food&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablets whole with water. Do not break, crush, or chew the tablets. This will ensure the medicine works as well as possible.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Akeega is taken with a medicine called prednisone or prednisolone.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take the prednisone or prednisolone exactly as your doctor has told you.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You need to take prednisone or prednisolone every day while you are taking Akeega.</p><p>o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The amount of prednisone or prednisolone you take may need to be changed if you have a medical emergency. Your doctor will tell you if you need to change the amount of prednisone or prednisolone you take. Do not stop taking prednisone or prednisolone unless your doctor tells you to.</p><p>&nbsp;</p><p>Your doctor may also prescribe other medicines while you are taking Akeega.</p><p>&nbsp;</p><p><strong>If you take more Akeega than you should</strong></p><p>If you take more tablets than you should contact your doctor. You may have an increased risk of side effects.</p><p>&nbsp;</p><p><strong>If you forget to take Akeega</strong></p><p>If you forget to take Akeega or prednisone or prednisolone, take your usual dose as soon as you remember on the same day.</p><p>&nbsp;</p><p>If you forget to take Akeega or prednisone or prednisolone for more than one day ‑ talk to your doctor straight away.</p><p>&nbsp;</p><p>Do not take a double dose to make up for a forgotten dose.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p><p><strong>If you stop taking Akeega</strong></p><p>Do not stop taking Akeega or prednisone or prednisolone unless your doctor tells you to.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p><strong>Serious side effects</strong></p><p><strong>Stop taking Akeega and seek medical attention immediately if you notice any of the following symptoms:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Very common </strong>(may affect more than 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising or bleeding for longer than usual if you hurt yourself ‑ these may be signs of a low blood platelet count (thrombocytopenia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Being short of breath, feeling very tired, having pale skin, or fast heartbeat ‑ these may be signs of a low red blood cell count (anaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever or infection &ndash; low white blood cell count (neutropenia) can increase your risk for infection. Signs may include fever, chills, feeling weak or confused, cough, pain or burning feeling when passing urine. Some infections can be serious and may lead to death.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle weakness, muscle twitching or a pounding heart beat (palpitations). These may be signs that the level of potassium in your blood is low (hypokalaemia).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Increased level of the enzyme &lsquo;alkaline phosphatase&rsquo; in the blood</p><p>&nbsp;</p><p><strong>Not known </strong>(cannot be estimated) &ndash; not reported with the use of Akeega but reported with use of niraparib or abiraterone acetate (components of Akeega)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction (including severe allergic reaction that can be life-threatening). Signs include:</p><p>raised and itchy rash (hives) and swelling‑sometimes of the face or mouth (angioedema),</p><p>causing difficulty in breathing, and collapse or loss of consciousness.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A sudden increase in blood pressure, which may be a medical emergency that could lead to organ damage or can be life-threatening.</p><p>&nbsp;</p><p><strong>Other side effects</strong></p><p>Talk to your doctor if you get any other side effects. These can include:</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; urinary tract infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of white blood cells (leukopenia), seen in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low number of a type of white blood cell (lymphopenia), seen in blood tests</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decreased appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty sleeping (insomnia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; constipation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; back pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of sugar in blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; swollen hands, ankles, or feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of &lsquo;creatinine&rsquo; in the blood</p><p>&nbsp;</p><p><strong>Common </strong>(may affect up to 1 in 10 people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pneumoniae</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infection (bronchitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; infection of the nose and throat (nasopharyngitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; high level of a type of fat (hypertriglyceridaemia) in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling anxious</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast heart beat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fast or uneven heart beat (palpitations)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; irregular heart beat (atrial fibrillation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart failure, causing shortness of breath and swollen legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heart attack</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest discomfort, often brought on by physical activity</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood clot in the lungs, causing chest pain and shortness of breath</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed lungs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; indigestion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bloating</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sores in the mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dry mouth</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver failure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle aches</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; blood in the urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the enzyme &lsquo;aspartate aminotransferase&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of the enzyme &lsquo;alanine aminotransferase&rsquo; in the blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; bone fractures</p><p>&nbsp;</p><p><strong>Uncommon </strong>(may affect up to 1 in 100&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; severe infection (sepsis) that spreads from the urinary tract throughout the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed eye (conjunctivitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling confused</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; change in sense of taste</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; abnormal ECG (electrocardiogram), which could be a sign of heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nose bleeds</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflammation of the protective linings in the body cavities, such as the nose, mouth, or digestive system</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased sensitivity of the skin to sunlight</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increased level of &lsquo;gamma-glutamyltransferase&rsquo; in the blood</p><p>&nbsp;</p><p><strong>Not known </strong>(cannot be estimated) &ndash; not reported with the use of Akeega but reported with use of niraparib or abiraterone acetate (components of Akeega)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; low numbers of all types of blood cells (pancytopenia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; brain condition with symptoms including seizures (fits), headache, confusion, and changes in vision (posterior reversible encephalopathy syndrome or PRES), which is a medical emergency that could lead to organ damage or can be life-threatening</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; adrenal gland problems (related to salt and water problems) where too little hormone is produced which may cause problems like weakness, tiredness, loss of appetite, nausea, dehydration and skin changes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty thinking, remembering information, or solving problems (cognitive impairment)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; inflamed lungs caused by an allergic reaction (allergic alveolitis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle disease (myopathy), which may cause muscle weakness, stiffness or spasms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; breakdown of muscle tissue (rhabdomyolysis), which may cause muscle cramps or pains, tiredness and dark urine</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the container (blister foil, inner wallet, outer wallet, and carton) after EXP. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Akeega contains</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are niraparib and abiraterone acetate. Each film-coated tablet contains 100&nbsp;mg niraparib and 500&nbsp;mg abiraterone acetate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients of the tablet core are colloidal anhydrous silica, crospovidone, hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, sodium lauryl sulfate. The film‑coating contains iron oxide red (E172), iron oxide yellow (E172), sodium lauryl sulphate, glycerol monocaprylocaprate, polyvinyl alcohol, talc, and titanium dioxide (E171) (see section 2, Akeega contains lactose and sodium)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Akeega film-coated tablets are orange oval tablets, debossed with “N 100 A” on one side and plain on the other side.

Each 28-day carton contains 56 film-coated tablets in two cardboard wallet packs of 28 film-coated tablets each.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong></p><p>Janssen‑Cilag International NV</p><p>Turnhoutseweg 30</p><p>B‑2340 Beerse</p><p>Belgium</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Manufacturer</strong></p><p>Patheon France S.A.S,</p><p>40 Boulevard de Champaret</p><p>Bourgoin Jallieu 38 300, France</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                To contact us, go to www.janssen.com/contact-us

	This leaflet was last revised on 11 July 2024.

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">أكيجا هو دواء يحتوي على مادتين فعالتين: نيراباريب وأبيراتيرون أسيتات، ويعمل بطريقتين مختلفتين.</p><p>&nbsp;</p><p dir="RTL">يُستخدم أكيجا لعلاج الرجال البالغين المصابين بسرطان البروستاتا الذين يعانون من تغيرات في جينات معينة ممن انتشر سرطان البروستاتا لديهم في أجزاء أخرى من الجسم ولم يعد يستجيب للعلاج الطبي أو الجراحي الذي يخفض هرمون التستوستيرون (يُطلق عليه أيضًا سرطان البروستاتا النقيلي المقاوم للإخصاء).</p><p>&nbsp;</p><p dir="RTL">نيراباريب هو نوع من أدوية السرطان يُطلق عليه مثبط PARP. تعمل مثبطات PARP على إحصار إنزيم يُسمى بوليميراز [ريبوز ثنائي فوسفات الأدينوزين] المتعدد (PARP). يعمل إنزيم PARP على مساعدة الخلايا على إصلاح الحمض النووي (DNA) التالف. وعندما يتم إحصار إنزيم PARP، لا تستطيع الخلايا السرطانية إصلاح حمضها النووي (DNA)، مما يؤدي إلى موت خلايا الورم والمساعدة في السيطرة على السرطان.</p><p>&nbsp;</p><p dir="RTL">يوقف أبيراتيرون عملية إنتاج الجسم لهرمون التستوستيرون؛ وهذا من شأنه أن يبطئ من نمو سرطان البروستاتا.</p><p>&nbsp;</p><p dir="RTL">عند استخدام هذا الدواء، سيصف لك طبيبك أيضًا دواءً آخر يسمى بريدنيزون أو بريدنيزولون. وهذا لتقليل احتمال إصابتك بارتفاع ضغط الدم، أو كثرة الماء في جسمك (احتباس السوائل)، أو انخفاض مستويات مادة كيميائية تُعرف بالبوتاسيوم في دمك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول أكيجا في الحالات الآتية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية ضد نيراباريب أو أبيراتيرون أسيتات أو أي من المكونات الأخرى في هذا الدواء - مدرجة في القسم 6.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ امرأة حاملاً أو قد تصبحين حاملاً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من تلف شديد في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بالتزامن مع علاج راديوم223 &nbsp;( Ra-223) الإشعاعي (الذي يستخدم لعلاج سرطان البروستاتا). وهذا بسبب احتمالية زيادة خطر الإصابة بكسور العظام أو الوفاة.</p><p>&nbsp;</p><p dir="RTL">لا تتناول هذا الدواء إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك. إذا لم تكن متأكدًا، فاستشر طبيبك أو الصيدلي قبل استخدام هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL">استشر طبيبك أو الصيدلي قبل أو أثناء تناول هذا الدواء إذا كنت تعاني من:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض تعداد خلايا الدم. تشمل العلامات والأعراض التي تحتاج إلى الانتباه لها، الإرهاق، والحمى أو العدوى، والتكدم أو النزيف غير الطبيعي. قد يقلل أكيجا أيضًا تعداد خلايا الدم لديك. وسيقوم طبيبك بفحص دمك بانتظام طوال فترة العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم، أو السكتة القلبية، أو انخفاض البوتاسيوم في الدم (قد يؤدي انخفاض البوتاسيوم في الدم إلى زيادة خطر حدوث مشكلات في نظم القلب)، أو إذا سبق أن أُصبت بمشكلات أخرى في القلب أو الأوعية الدموية، أو تعاني من ضربات قلب غير منتظمة أو سريعة، أو ضيق في التنفس، أو إذا كنت تكتسب وزنًا بسرعة، أو تعاني من تورم في القدمين، أو الكاحلين، أو الساقين. وسيقوم طبيبك بقياس ضغط دمك بانتظام طوال فترة العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، أو تغيرات في الرؤية، أو تشوش، أو نوبة صرع. فقد تكون هذه علامات لأثر جانبي عصبي نادر يُسمى متلازمة اعتلال الدماغ الخلفي القابل للعكس (PRES) التي اقترنت باستخدام نيراباريب، أحد المواد الفعالة لدواء أكيجا.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى مرتفعة، وإرهاق، وعلامات وأعراض أخرى تشير إلى الإصابة بعدوى شديدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطات دموية في الرئتين أو الساقين، أو سبقت لك الإصابة بها في الماضي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض مستويات السكر في الدم أو ارتفاعها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات و/أو ألم العضلات.</p><p>&nbsp;</p><p dir="RTL">إذا كانت أي من الحالات المذكورة أعلاه تنطبق عليك (أو إذا لم تكن متأكدًا)، فاستشر طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL">إذا كنت تعاني من تعداد غير طبيعي لخلايا الدم لفترة طويلة من الوقت أثناء تناول أكيجا، فقد تكون هذه علامة لمشكلات أكثر خطورة في النخاع العظمي مثل &quot;متلازمة خلل التنسج النقوي&quot; (MDS) أو &quot;ابيضاض الدم النخاعي الحاد&quot; (AML). وقد يرغب طبيبك في فحص النخاع العظمي لديك للتحقق من هذه المشكلات.</p><p>&nbsp;</p><p dir="RTL">قبل تناول أكيجا، استشر طبيبك أو الصيدلي أيضًا بشأن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التأثير الذي قد يسببه أكيجا على عظامك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول بريدنيزون أو بريدنيزولون (دواء آخر يجب عليك تناوله مع أكيجا).</p><p>&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا من أن أيًّا مما ذُكِرَ أعلاه ينطبق على حالتك، فاستشر طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p>&nbsp;</p><p dir="RTL"><strong>مراقبة الدم</strong></p><p dir="RTL">قد يؤثر أكيجا على الكبد، لكنك قد لا تلاحظ أي أعراض تشير إلى مشكلات بالكبد. لذا عند قيامك بتناول هذا الدواء، سيقوم طبيبك بفحص دمك بشكل دوري للتحقق من أي آثار على الكبد.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">هذا الدواء لا يُستخدم مع الأطفال والمراهقين. في حالة ابتلاع طفل أو مراهق دواء أكيجا بطريق الخطأ، اذهب بهم إلى المستشفى على الفور واصطحب نشرة العبوة هذه معك لعرضها على طبيب الطوارئ.</p><p>&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وأكيجا</strong></p><p dir="RTL">يُرجى إبلاغ طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى. هذا لأن أكيجا يمكنه أن يؤثر على مفعول بعض الأدوية الأخرى. ويمكن لبعض الأدوية الأخرى أيضًا أن تؤثر على مفعول أكيجا.</p><p>&nbsp;</p><p dir="RTL">قد يؤدي العلاج بالأدوية التي توقف عملية إنتاج الجسم لهرمون التستوستيرون إلى زيادة خطر حدوث مشكلات في نظم القلب. أخبر طبيبك إذا كنت تتناول أدوية:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>لعلاج مشكلات نظم القلب (مثل كوينيدين، وبروكاييناميد، وأميودارون، وسوتالول)؛</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>معروف عنها أنها تزيد من خطر حدوث مشكلات في نظم القلب (مثل ميثادون)، المستخدم لتخفيف الآلام وضمن العلاج المستخدم لتخليص الجسم من سموم إدمان المخدرات؛ وموكسيفلوكساسين، مضاد حيوي؛ ومضادات الذهان، المستخدمة لعلاج الأمراض العقلية الخطيرة.</p><p>&nbsp;</p><p dir="RTL">أخبر طبيبك إذا كنت تتناول أيًا من الأدوية المذكورة أعلاه.</p><p>&nbsp;</p><p dir="RTL"><strong>أكيجا والطعام</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يجب عدم تناول هذا الدواء مع الطعام (انظر القسم&nbsp;3، &quot;تناول أكيجا&quot;)، حيث قد يزيد ذلك من خطر حدوث الآثار الجانبية لديك.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL">لا يُستخدم أكيجا لعلاج النساء.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>قد يضر هذا الدواء بالجنين إذا تناولته امرأة حامل.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>يجب أن ترتدي النساء الحوامل أو اللاتي قد يصبحن حوامل قفازات عند الحاجة إلى لمس أكيجا أو التعامل معه.</p><p dir="RTL">وسائل منع الحمل للرجال الذين يتناولون أكيجا</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>في حالة المعاشرة الزوجية لزوجتك القادرة على الإنجاب، استخدم واقيًا ذكريًا بالإضافة إلى وسيلة أخرى فعالة لمنع الحمل. واحرص على استخدام وسائل منع الحمل أثناء العلاج ولمدة 4 أشهر بعد إيقافه. استشر طبيبك إذا كان لديك أي أسئلة تتعلق بوسائل منع الحمل.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>في حالة المعاشرة الزوجية لزوجتك أثناء الحمل، استخدم واقيًا ذكريًا لحماية الجنين.</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">قد تشعر بالضعف أو عدم التركيز أو التعب أو الدوار عند تناول أكيجا. وقد يؤثر ذلك في قدرتك على القيادة واستخدام الآلات. كن حذرًا عند القيادة أو استخدام الآلات.</p><p>&nbsp;</p><p dir="RTL"><strong>يحتوي أكيجا على اللاكتوز والصوديوم</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحتوي أكيجا على اللاكتوز. إذا أخبرك طبيبك بأنك تعاني من عدم القدرة على تحمل بعض السكريات، فاستشره قبل تناول هذا الدواء.</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1&nbsp;ملليمول من الصوديوم (23&nbsp;مجم) لكل جرعة؛ أي أنه &nbsp;يعد &quot;خاليًا من الصوديوم&quot; في الأساس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا كما أخبرك الطبيب تمامًا. راجع طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة الدوائية</strong></p><p dir="RTL">جرعة البداية الموصى بها هي 200&nbsp;مجم/1000 مجم (قرصان) مرة واحدة يوميًا.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول أكيجا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يؤخذ هذا الدواء عن طريق الفم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تتناول أكيجا مع الطعام.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول أقراص أكيجا كجرعة فردية مرة واحدة يوميًا على معدة خاوية<strong> قبل ساعة واحدة على الأقل أو بعد ساعتين على الأقل من تناول الطعام</strong> (انظر القسم 2، &quot;أكيجا والطعام&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابلع الأقراص كاملةً مع الماء. ولا تقم بتكسير الأقراص أو سحقها أو مضغها. فهذا سيضمن أفضل فعالية ممكنة للدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتم تناول أكيجا مع دواء يُسمى بريدنيزون أو بريدنيزولون.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول بريدنيزون أو بريدنيزولون كما أخبرك الطبيب تمامًا.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يتعين عليك تناول بريدنيزون أو بريدنيزولون يوميًا أثناء تناول أكيجا.</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يلزم تغيير مقدار جرعة بريدنيزون أو بريدنيزولون التي تتناولها في حالة تعرضك لحالة طبية طارئة. سيخبرك طبيبك إذا لزم الأمر تغيير مقدار جرعة بريدنيزون أو بريدنيزولون التي تتناولها. لا تتوقف عن تناول بريدنيزون أو بريدنيزولون إلا عندما يخبرك الطبيب بهذا.</p><p>&nbsp;</p><p dir="RTL">قد يصف لك طبيبك كذلك أدوية أخرى أثناء تناولك دواء أكيجا.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا تناولت أكيجا بجرعة أكبر مما ينبغي</strong></p><p dir="RTL">إذا تناولت أقراصًا أكثر مما ينبغي لك، يجب عليك الاتصال بطبيبك. فقد تكون معرضًا لزيادة خطر الإصابة بالآثار الجانبية.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول أكيجا</strong></p><p dir="RTL">إذا نسيت تناول أكيجا أو بريدنيزون أو بريدنيزولون، فتناول جرعتك المعتادة بمجرد أن تتذكرها في اليوم نفسه.</p><p>&nbsp;</p><p dir="RTL">إذا نسيت تناول أكيجا أو بريدنيزون أو بريدنيزولون لأكثر من يوم واحد، فاستشر طبيبك على الفور.</p><p>&nbsp;</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض جرعة منسية.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاطرحها على طبيبك أو الصيدلي أو الممرضة.</p><p>&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول أكيجا</strong></p><p dir="RTL">لا تتوقف عن تناول أكيجا أو بريدنيزون أو بريدنيزولون إلا عندما يخبرك الطبيب بهذا.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك أي أسئلة إضافية بشأن استخدام هذا الدواء، فاطرحها على طبيبك أو الصيدلي أو الممرضة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يُسبب هذا الدواء آثارًا جانبية، على الرغم من عدم إصابة الجميع بها.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الخطيرة</strong></p><p dir="RTL"><strong>توقف عن تناول أكيجا واحصل</strong><strong> </strong><strong>على رعاية طبية على الفور إذا لاحظت أيًا من الأعراض الآتية:</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تصيب أكثر من شخص واحد من كل 10 أشخاص)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تكدم أو نزيف لفترة أطول من المعتاد إذا جرحت نفسك - قد تكون هذه علامات لانخفاض تعداد الصفائح الدموية (قلة الصفيحات).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق التنفس، أو الشعور بالتعب الشديد، أو شحوب الجلد، أو سرعة ضربات القلب - قد تكون هذه علامات لانخفاض تعداد خلايا الدم الحمراء (فقر الدم/الأنيميا).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمى أو عدوى - يمكن أن يؤدي انخفاض تعداد خلايا الدم البيضاء (قلة العدلات) إلى زيادة خطر إصابتك بالعدوى. قد تشمل العلامات الحمى، أو القشعريرة، أو الشعور بالضعف أو التشوش، أو السعال، أو الألم أو الشعور بالحرقان عند التبول. قد تكون بعض أنواع العدوى خطيرة وقد تؤدي إلى الوفاة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات، أو تشنج العضلات، أو ضربات قلب عنيفة (خفقان). قد تكون هذه علامات لانخفاض مستوى البوتاسيوم في دمك (نقص بوتاسيوم الدم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم &quot;الفوسفاتيز القلوية&quot; في الدم</p><p>&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقديرها) - لم يتم الإبلاغ عن حدوثها عند استخدام أكيجا، لكن تم الإبلاغ عن حدوثها عند استخدام نيراباريب أو أبيراتيرون أسيتات (مكونات أكيجا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي (بما في ذلك رد الفعل التحسسي الشديد الذي قد يكون مهددًا للحياة). وتشتمل العلامات على:</p><p dir="RTL">طفح جلدي بارز ومثير للحكة (الشرى) وتورم - أحيانًا في الوجه أو الفم (وذمة وعائية)،</p><p dir="RTL">ما يسبب صعوبة في التنفس، والإغماء أو فقدان الوعي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مفاجئ في ضغط الدم، قد يمثل حالة طبية طارئة يمكنها أن تؤدي إلى تلف الأعضاء أو قد تكون مهددة للحياة.</p><p>&nbsp;</p><p dir="RTL"><strong>الأعراض الجانبية الأخرى</strong></p><p dir="RTL">إذا أُصبت بأي آثار جانبية أخرى، فاستشر طبيبك. وقد تشمل الآتي:</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة جدًا </strong>(قد تصيب أكثر من شخص واحد من كل 10&nbsp;أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى المسالك البولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد خلايا الدم البيضاء (قلة الكريات البيضاء)، الذي يظهر في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد نوع من خلايا الدم البيضاء (نقص الخلايا اللمفاوية)، الذي يظهر في اختبارات الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع ضغط الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم (الأرق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإمساك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالرغبة في التقيؤ (الغثيان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم الظهر</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتعب الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى السكر في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم اليدين أو الكاحلين أو القدمين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع مستوى &quot;الكرياتينين&quot; في الدم</p><p>&nbsp;</p><p dir="RTL"><strong>شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من كل 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الرئة (التهاب الشعب الهوائية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى في الأنف والحلق (التهاب البلعوم الأنفي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نسبة نوع من الدهون (فرط ثلاثي غليسيريد الدم) في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالقلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة ضربات القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرعة أو ضربات القلب غير متساوية (خفقان)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدم انتظام ضربات القلب (رجفان أذيني)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل القلب ، تسبب ضيق في التنفس وتورم الساقين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذبحة القلبية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق في الصدر، يحدث غالبًا بسبب النشاط البدني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جلطة دموية في الرئتين مسببة ألمًا في الصدر وضيق في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عسر الهضم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانتفاخ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرح الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جفاف الفم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فشل الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام العضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور دم في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم &quot; ناقلة أمين الاسبرتات &quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم &quot; ناقلة أمين الألانين &quot; في الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كسور العظام</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة </strong>(قد تصيب ما يصل إلى شخص واحد من كل 100&nbsp;شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى شديدة (تعفن) تنتشر من المسالك البولية في جميع أنحاء الجسم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب العين (التهاب الملتحمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالتشوش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغير في حاسة التذوق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نتائج غير طبيعية في ECG (الرسم الكهربي للقلب)، يمكن أن تكون علامة لوجود مشكلات في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف الأنف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب في البطانات الواقية الموجودة في تجاويف الجسم مثل الأنف، أو الفم، أو الجهاز الهضمي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة حساسية الجلد لأشعة الشمس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة مستوى إنزيم &quot;ناقلة الجاما-جلوتاميل&quot; في الدم</p><p>&nbsp;</p><p dir="RTL"><strong>غير معروفة </strong>(لا يمكن تقديرها) - لم يتم الإبلاغ عن حدوثها عند استخدام أكيجا، لكن تم الإبلاغ عن حدوثها عند استخدام نيراباريب أو أبيراتيرون أسيتات (مكونات أكيجا)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض عدد جميع أنواع خلايا الدم (قلة الكريات الشاملة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالة في الدماغ تشمل أعراضها نوبات (نوبات تشنجية)، وصداع، وتشوش، وتغيرات في الرؤية (متلازمة اعتلال الدماغ الخلفي القابل للعكس أو PRES)، وهي تمثل حالة طبية طارئة يمكن أن تؤدي إلى تلف الأعضاء أو قد تكون مهددة للحياة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشكلات في الغدة الكظرية (متعلقة بمشكلات الملح والماء) حيث يتم إفراز قدر ضئيل للغاية من الهرمون، ما قد يسبب مشكلات مثل الضعف، والتعب، وفقدان الشهية، والغثيان، والجفاف، وتغيرات في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التفكير، أو تذكر المعلومات، أو حل المشكلات (ضعف الإدراك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب الرئتين الناجم عن رد فعل تحسسي (التهاب الحويصلات الهوائية التحسسي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مرض عضلي (اعتلال عضلي)، قد يسبب ضعف العضلات أو تصلبها أو تشنجاتها</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تمزق في الأنسجة العضلية (انحلال الربيدات)، الذي قد يسبب تشنجات العضلات أو آلامها، والشعور بالتعب، والبول الداكن</p><p>&nbsp;</p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية:</strong></p><p>إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو الصيدلي.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p>&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الحاوية (رقاقة البليستر، والحافظة الداخلية، والحافظة الخارجية، والعبوة الكرتونية) بعد &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى آخر يوم من الشهر المذكور.</p><p>&nbsp;</p><p dir="RTL">يُخزن في درجة حرارة أقل من 30 درجة مئوية.</p><p>&nbsp;</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو المخلفات المنزلية. اسأل الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد بحاجة إلى استخدامها. فهذه التدابير ستساعد على حماية البيئة.</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتوى دواء أكيجا</strong></p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>المواد الفعالة هي نيراباريب وأبيراتيرون أسيتات. يحتوي كل قرص مغلف بطبقة رقيقة على 100&nbsp;مجم نيراباريب و500&nbsp;مجم أبيراتيرون أسيتات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى للقرص هي: السيليكا اللامائية الغروانية، وكروسبوفيدون، وهيبروميلوز، ولاكتوز أحادي الإماهة، وستيرات الماغنيسيوم، وسيليلوز بلوري مِكرويّ، وكبريتات لوريل الصوديوم. تحتوي الطبقة المغلفة على أكسيد الحديد الأحمر (E172)، وأكسيد الحديد الأصفر (E172)، وكبريتات لوريل الصوديوم، وجليسرول أحادي الكابريلوكابرات، وكحول البولي فينيل، وتلك، وثاني أكسيد التيتانيوم (E171)، (انظر القسم 2، يحتوي أكيجا على اللاكتوز والصوديوم)</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>شكل أكيجا ومحتويات العبوة</strong></p><p dir="RTL">أقراص أكيجا المغلفة بطبقة رقيقة عبارة عن أقراص بيضاوية برتقالية اللون، مطبوع على أحد جانبيها الرمز &quot;N 100 A&quot; ودون طباعة على الجانب الآخر.</p><p>&nbsp;</p><p dir="RTL">كل عبوة كرتونية مخصصة لعلاج 28 يومًا تحتوي على 56 قرصًا مغلفًا بطبقة رقيقة في اثنين من العبوات الحافظة من الورق المقوى تشمل كل منها 28 قرصًا مغلفًا بطبقة رقيقة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حامل الرخصة التسويقية</strong></p><p>جانسن سيلاج إنترناشيونال ان في</p><p>تورنھوتسویج &nbsp;30</p><p>بي-2340 بيرس</p><p>بلجيكا</p><p>&nbsp;</p><p dir="RTL"><strong>الشركة المصنّعة</strong></p><p>باثيون فرنسا اس. إيه. اس</p><p>40 بوليفارد دو شامباريه</p><p>300 38 بورجوين جاليو</p><p>فرنسا</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            للتواصل معنا، يُرجى زيارة موقعنا الإلكتروني www.janssen.com/contact-us

تمت آخر مراجعة لهذه النشرة في 11 يوليو 2024.

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Akeega 50 mg/500 mg film-coated tablets 
Akeega 100 mg/500 mg film-coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Akeega 50 mg/500 mg film-coated tablets
Each film-coated tablet contains niraparib tosylate monohydrate equivalent to 50 mg of niraparib and 500 mg of abiraterone acetate equivalent to 446 mg of abiraterone.

Akeega 100 mg/500 mg film-coated tablets
Each film-coated tablet contains niraparib tosylate monohydrate equivalent to 100 mg of niraparib and 500 mg of abiraterone acetate equivalent to 446 mg of abiraterone.

Excipients with known effect
Each film-coated tablet contains 241 mg of lactose (see section 4.4) For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).

Akeega 50 mg/500 mg film-coated tablets
Yellowish orange to yellowish brown, oval, film-coated tablets (22 mm x 11 mm), debossed with “N 50 A” on one side, and plain on the other side.

Akeega 100 mg/500 mg film-coated tablets
Orange, oval, film-coated tablets (22 mm x 11 mm), debossed with “N 100 A” on one side, and plain on the other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Akeega is indicated with prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA 1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with niraparib and abiraterone acetate plus prednisone or prednisolone should be initiated and supervised by specialist physicians experienced in the medical treatment of prostate cancer.</p><p>&nbsp;</p><p>Before initiation of Akeega therapy, positive BRCA status must be established using a validated test method (see section 5.1).</p><p>&nbsp;</p><p><u>Posology</u></p><p>The recommended starting dose of Akeega is 200 mg/1 000 mg (two 100 mg niraparib/500 mg abiraterone acetate tablets), as a single daily dose at approximately the same time every day (see &ldquo;Method of administration&rdquo; below). The 50 mg/500 mg tablet is available for dose reduction.</p><p>&nbsp;</p><p>Medical castration with a gonadotropin-releasing hormone (GnRH) analogue should be continued during treatment in patients not surgically castrated.</p><p>&nbsp;</p><p><em>Dosage of prednisone or prednisolone</em></p><p>Akeega is used with 10 mg prednisone or prednisolone daily.</p><p>&nbsp;</p><p><em>Duration of treatment</em></p><p>Patients should be treated until disease progression or unacceptable toxicity.</p><p>&nbsp;</p><p><em>Missed dose</em></p><p>If a dose of either Akeega, prednisone or prednisolone is missed, it should be taken as soon as possible on the same day with a return to the normal schedule the following day. Extra tablets must not be taken to make up for the missed dose.</p><p>&nbsp;</p><p><em>Dose adjustments for adverse reactions <u>Non-haematological adverse reactions</u></em></p><p>For patients who develop Grade &ge; 3 non-haematological adverse reactions, treatment should be interrupted and appropriate medical management should be instituted (see section 4.4). Treatment with Akeega should not be reinitiated until symptoms of the toxicity have resolved to Grade 1 or baseline.</p><p>&nbsp;</p><p><em><u>Haematological adverse reactions</u></em></p><p>For patients who develop a &ge; Grade 3 or intolerable haematological toxicity, dosing with Akeega should be interrupted rather than discontinued and supportive management considered. Akeega should be permanently discontinued if haematological toxicity has not returned to acceptable levels within</p><p>28 days of the dose interruption period.</p><p>&nbsp;</p><p>The dose adjustment recommendations for thrombocytopenia and neutropenia are listed in Table 1.</p><p>&nbsp;</p><p>Table 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose adjustment recommendations for thrombocytopenia and neutropenia</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Grade 1</p></td><td style="vertical-align:top"><p>No change, consider weekly monitoring</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2</p></td><td style="vertical-align:top"><p>At least weekly monitoring and consider withholding Akeega until recovery to Grade 1 or baseline.<sup>1</sup> Resume Akeega with recommendation of weekly monitoring for 28 days after restarting dose.</p></td></tr><tr><td style="vertical-align:top"><p>Grade &ge; 3</p></td><td style="vertical-align:top"><p>Withhold Akeega and monitor at least weekly until platelets and neutrophils recover to Grade 1 or baseline.<sup>1</sup> Then resume Akeega or, if warranted, use <strong>two lower strength </strong>tablets (50 mg/500 mg).</p><p><strong>&nbsp;</strong></p><p>Weekly monitoring of blood counts is recommended for 28 days after restarting dose or starting the <strong>lower strength </strong>dose (two 50 mg/500 mg tablets). When starting the <strong>lower strength </strong>dose, please refer to &ldquo;Recommended monitoring&rdquo; below for further information regarding liver function.</p></td></tr><tr><td style="vertical-align:top"><p>Second occurrence</p><p>&ge; grade 3</p></td><td style="vertical-align:top"><p>Withhold Akeega and monitor at least weekly until platelets and/or neutrophils recover to Grade 1. Further treatment should restart with <strong>two lower strength </strong>tablets (50 mg/500 mg)<strong>.</strong></p><p><strong>&nbsp;</strong></p><p>Weekly monitoring is recommended for 28 days after resuming treatment with <strong>lower strength Akeega</strong>. When starting the <strong>lower strength </strong>dose (two 50 mg/500 mg tablets), please refer to &ldquo;Recommended monitoring&rdquo; below for further information regarding liver function.</p><p><strong>&nbsp;</strong></p><p>If patient was already on <strong>lower strength Akeega tablet (50 mg/500 mg),</strong></p><p>consider treatment discontinuation.</p></td></tr><tr><td style="vertical-align:top"><p>Third occurrence</p><p>&ge; grade 3</p></td><td style="vertical-align:top"><p>Permanently discontinue treatment.</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:group
 id="Group_x0020_115" o:spid="_x0000_s1026" style='width:453.6pt;height:.5pt;
 mso-position-horizontal-relative:char;mso-position-vertical-relative:line'
 coordsize="9072,10" o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:rect id="Rectangle_x0020_116" o:spid="_x0000_s1027" style='position:absolute;
  width:9072;height:10;visibility:visible;mso-wrap-style:square;
  v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" fillcolor="black" stroked="f"/>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
 id="_x0000_i1025" type="#_x0000_t75" style='width:453.6pt;height:.5pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--></p><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During Akeega treatment interruption, abiraterone acetate and prednisone or prednisolone may be considered by the physician and given to maintain daily dose of abiraterone acetate (see abiraterone acetate prescribing information).</p><p>&nbsp;</p><p>Further dosing with Akeega may be resumed only when toxicity due to thrombocytopenia and neutropenia is improved to Grade 1 or resolved to baseline. Treatment may resume at a lower strength of Akeega 50 mg/500 mg (2 tablets). For the most common adverse reactions, see section 4.8.</p><p>&nbsp;</p><p>For Grade &ge;3 anaemia, Akeega should be interrupted and supportive management provided until recovered to Grade &le;2. Dose reduction (two 50 mg/500 mg tablets) should be considered if anaemia persists based on clinical judgment. The dose adjustment recommendations for anaemia are listed in Table 2.</p><p>&nbsp;</p><p>Table 2:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose adjustment recommendations for anaemia</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Grade 1</p></td><td style="vertical-align:top"><p>No change, consider weekly monitoring.</p></td></tr><tr><td style="vertical-align:top"><p>Grade 2</p></td><td style="vertical-align:top"><p>At least weekly monitoring for 28 days, if baseline anaemia was Grade &le; 1.</p></td></tr><tr><td style="vertical-align:top"><p>Grade &ge; 3</p></td><td style="vertical-align:top"><p>Withhold Akeega<sup>1</sup> and provide supportive management with monitoring at least weekly until recovered to Grade &le; 2. Dose reduction [<strong>two lower strength tablets (50 mg/500 mg)</strong>] should be considered if anaemia persists based on clinical judgment. When starting the <strong>lower strength </strong>dose, please refer to &ldquo;Recommended monitoring&rdquo; below for further information regarding liver function.</p></td></tr><tr><td style="vertical-align:top"><p>Second occurrence</p><p>&ge; Grade 3</p></td><td style="vertical-align:top"><p>Withhold Akeega, provide supportive management and monitor at least weekly until recovered to Grade &le; 2. Further treatment should restart with <strong>two lower strength tablets (50 mg/500 mg).</strong></p><p>Weekly monitoring is recommended for 28 days after resuming treatment with <strong>lower strength Akeega</strong>. When starting the <strong>lower strength </strong>dose, please refer to &ldquo;Recommended monitoring&rdquo; below for further information regarding liver function.</p><p>If patient was already on <strong>lower strength Akeega tablet (50 mg/500 mg),</strong></p><p>consider treatment discontinuation.</p></td></tr><tr><td style="vertical-align:top"><p>Third occurrence</p><p>&ge; Grade 3</p></td><td style="vertical-align:top"><p>Consider discontinuing treatment with Akeega based on clinical judgment.</p></td></tr></tbody></table><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During Akeega treatment interruption, abiraterone acetate and prednisone or prednisolone may be considered by the physician and given to maintain daily dose of abiraterone acetate (see abiraterone acetate prescribing information).</p><p>&nbsp;</p><p><em>Hepatotoxicity</em></p><p>For patients who develop &ge; Grade 3 hepatotoxicity (alanine aminotransferase [ALT] increases or aspartate aminotransferase [AST] increases above five times the upper limit of normal [ULN]), treatment with Akeega should be interrupted and liver function closely monitored (see section 4.4).</p><p>&nbsp;</p><p>Re-treatment may take place only after return of liver function tests to the patient&rsquo;s baseline and at a reduced dose level of one regular strength Akeega tablet (equivalent to 100 mg niraparib/500 mg abiraterone acetate). For patients being re-treated, serum transaminases should be monitored at a minimum of every two weeks for three months and monthly thereafter. If hepatotoxicity recurs at the reduced dose of 100 mg/500 mg daily (1 tablet), treatment with Akeega should be discontinued.</p><p>&nbsp;</p><p>If patients develop severe hepatotoxicity (ALT or AST 20 times the ULN) while on Akeega, treatment should be permanently discontinued.</p><p>&nbsp;</p><p>Permanently discontinue Akeega for patients who develop a concurrent elevation of ALT greater than 3 &Iacute; ULN, and total bilirubin greater than 2 &Iacute; ULN, in the absence of biliary obstruction or other causes responsible for the concurrent elevation (see section 4.4).</p><p>&nbsp;</p><p><em>Recommended monitoring</em></p><p>Complete blood counts should be obtained prior to starting treatment, weekly for the first month, every two weeks for the next two months, followed by monthly monitoring for the first year and then every other month for the remainder of treatment to monitor for clinically significant changes in any haematologic parameter (see section 4.4).</p><p>&nbsp;</p><p>Serum aminotransferases and total bilirubin should be measured prior to starting treatment, every two weeks for the first three months of treatment and monthly thereafter for the first year and then every other month for the duration of treatment. When starting the lower strength dose (two tablets) after dose interruption, liver function should be monitored every two weeks for six weeks due to risk of increased abiraterone exposure (see section 5.2), before resuming regular monitoring. Serum potassium should be monitored monthly for the first year and then every other month for the duration of treatment (see section 4.4).</p><p>&nbsp;</p><p>Blood pressure monitoring should occur weekly for the first two months, monthly for the first year and then every other month for the duration of treatment.</p><p>&nbsp;</p><p>In patients with pre-existing hypokalaemia or those that develop hypokalaemia whilst being treated with Akeega, consider maintaining the patient&rsquo;s potassium level at &ge; 4.0 mM.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>No dose adjustment is necessary for elderly patients (see section 5.2).</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>No dose adjustment is necessary for patients with pre-existing mild hepatic impairment (Child-Pugh Class A). There are no data on the clinical safety and efficacy of multiple doses of Akeega when administered to patients with moderate or severe hepatic impairment (Child-Pugh Class B or C). No dose adjustment can be predicted. The use of Akeega should be cautiously assessed in patients with moderate hepatic impairment, in whom the benefit clearly should outweigh the possible risk (see sections 4.4 and 5.2). Akeega is contraindicated in patients with severe hepatic impairment (see sections 4.3, 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is necessary for patients with mild to moderate renal impairment, although close monitoring of safety events should be conducted with moderate renal impairment due to the potential for increased niraparib exposure. There are no data on the use of Akeega in patients with severe renal impairment or end stage renal disease undergoing haemodialysis, Akeega may only be used in patients with severe renal impairment if the benefit outweighs the potential risk, and the patient should be carefully monitored for renal function and adverse events (see sections 4.4 and 5.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>There is no relevant use of Akeega in the paediatric population.</p><p>&nbsp;</p><p><u>Method of administration</u> Akeega is for oral use.</p><p>The tablets must be taken as a single dose, once daily. Akeega should be taken on an empty stomach, at least 1 hour before or 2 hours after a meal (see section 5.2). For optimal absorption, Akeega tablets must be swallowed whole with water, they must not be broken, crushed, or chewed.</p><p>&nbsp;</p><p><em>Precaution to be taken before manipulating or administering the product</em></p><p>Women who are or may become pregnant should wear gloves when handling the tablets (see section 6.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances or to any of the excipients listed in section 6.1.
 
Women who are or may become pregnant (see section 4.6).

Severe hepatic impairment [Child-Pugh Class C (see sections 4.2, 4.4 and 5.2)].

Akeega plus prednisone or prednisolone is contraindicated in combination with Ra-223 treatment.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Haematological adverse reactions</u></p><p>Haematological adverse reactions (thrombocytopenia, anaemia and neutropenia) have been reported in patients treated with Akeega (see section 4.2).</p><p>&nbsp;</p><p>Testing complete blood counts weekly for the first month, every two weeks for the next two months, followed by monthly monitoring for the first year and then every other month for the remainder of treatment is recommended to monitor for clinically significant changes in any haematological parameter while on treatment (see section 4.2).</p><p>&nbsp;</p><p>Based on individual laboratory values, weekly monitoring for the second month may be warranted.</p><p>&nbsp;</p><p>If a patient develops severe persistent haematological toxicity including pancytopenia that does not resolve within 28 days following interruption, Akeega should be discontinued.</p><p>&nbsp;</p><p>Due to the risk of thrombocytopenia, other medicinal products known to reduce platelet counts should be used with caution in patients taking Akeega (see section 4.8).</p><p>&nbsp;</p><p>When starting the lower strength dose (two tablets) after dose interruption due to haematological adverse reactions, liver function should be monitored every two weeks for six weeks due to risk of increased abiraterone exposure (see section 5.2), before resuming regular monitoring (see section 4.2).</p><p>&nbsp;</p><p><u>Hypertension</u></p><p>Akeega may cause hypertension and pre-existing hypertension should be adequately controlled before starting Akeega treatment. Blood pressure should be monitored at least weekly for two months, monitored monthly afterwards for the first year and every other month thereafter during treatment with Akeega.</p><p>&nbsp;</p><p><u>Hypokalaemia, fluid retention, &amp; cardiovascular adverse reactions due to mineralocorticoid excess</u> Akeega may cause hypokalaemia and fluid retention (see section 4.8) as a consequence of increased mineralocorticoid levels resulting from CYP17 inhibition (see section 5.1). Co-administration of a corticosteroid suppresses adrenocorticotropic hormone (ACTH) drive, resulting in a reduction in incidence and severity of these adverse reactions. Caution is required in treating patients whose underlying medical conditions might be compromised by hypokalaemia (e.g., those on cardiac glycosides), or fluid retention (e.g., those with heart failure, severe or unstable angina pectoris, recent myocardial infarction or ventricular arrhythmia and those with severe renal impairment). QT prolongation has been observed in patients experiencing hypokalaemia in association with Akeega treatment. Hypokalaemia and fluid retention should be corrected and controlled.</p><p>&nbsp;</p><p>Before treating patients with a significant risk for congestive heart failure (e.g., a history of cardiac failure, or cardiac events such as ischaemic heart disease), cardiac failure should be treated and cardiac function optimised. Fluid retention (weight gain, peripheral oedema), and other signs and symptoms of congestive heart failure should be monitored every two weeks for three months, then monthly thereafter and abnormalities corrected. Akeega should be used with caution in patients with a history of cardiovascular disease.</p><p>&nbsp;</p><p>Management of cardiac risk factors (including hypertension, dyslipidaemia, and diabetes) should be optimised in patients receiving Akeega and these patients should be monitored for signs and symptoms of cardiac disease.</p><p>&nbsp;</p><p>Abiraterone acetate, a component of Akeega, increases mineralocorticoid levels and carries a risk for cardiovascular events. Mineralocorticoid excess may cause hypertension, hypokalaemia, and fluid retention. Previous androgen deprivation therapy (ADT) exposure as well as advanced age are additional risks for cardiovascular morbidity and mortality. The MAGNITUDE study excluded patients with clinically significant heart disease as evidenced by myocardial infarction, arterial and venous thrombotic events in the past six months, severe or unstable angina, or NYHA Class II to IV heart failure or cardiac ejection fraction measurement of &lt; 50%. Patients with a history of cardiac failure should be clinically optimised and appropriate management of symptoms instituted. If there is a clinically significant decrease in cardiac function, discontinuation of Akeega should be considered.</p><p>&nbsp;</p><p><u>Infections</u></p><p>In MAGNITUDE, severe infections including COVID-19 infections with fatal outcome occurred more frequently in patients treated with Akeega. Patients should be monitored for signs and symptoms of infection. Severe infections may occur in absence of neutropenia and/or leukopenia.</p><p>&nbsp;</p><p><u>Pulmonary embolism (PE)</u></p><p>In MAGNITUDE, cases of PE were reported in patients treated with Akeega with a higher frequency compared to control. Patients with a prior history of PE or venous thrombosis may be more at risk of a further occurrence. Patients should be monitored for clinical signs and symptoms of PE. If clinical features of PE occur, patients should be evaluated promptly, followed by appropriate treatment.</p><p>&nbsp;</p><p><u>Posterior reversible encephalopathy syndrome (PRES)</u></p><p>PRES is a rare, reversible, neurological disorder which can present with rapidly evolving symptoms including seizures, headache, altered mental status, visual disturbance, or cortical blindness, with or without associated hypertension. A diagnosis of PRES requires confirmation by brain imaging, preferably magnetic resonance imaging (MRI).</p><p>&nbsp;</p><p>There have been reports of PRES in patients receiving 300 mg niraparib (a component of Akeega) as a monotherapy in the ovarian cancer population. In the MAGNITUDE study, among prostate cancer patients treated with 200 mg of niraparib, there were no PRES cases reported.</p><p>&nbsp;</p><p>In case of PRES, treatment with Akeega should be permanently discontinued and appropriate medical management should be instituted.</p><p>&nbsp;</p><p><u>Hepatotoxicity and hepatic impairment</u></p><p>Hepatotoxicity had been recognised as an important identified risk for abiraterone acetate, a component of Akeega. The mechanism for hepatotoxicity of abiraterone acetate is not fully understood. Patients with moderate and severe hepatic impairment (NCI classification) and patients with Child-Turcotte-Pugh Class B and C were excluded from Akeega combination studies.</p><p>&nbsp;</p><p>In the MAGNITUDE study and all combination clinical studies, the risk for hepatotoxicity was mitigated by exclusion of patients with baseline hepatitis or significant abnormalities of liver function tests (Serum total bilirubin &gt; 1.5 &Iacute; ULN or direct bilirubin &gt; 1 &Iacute; ULN and AST or ALT</p><p>&gt; 3 &Iacute; ULN).</p><p>&nbsp;</p><p>Marked increases in liver enzymes leading to treatment interruption or discontinuation occurred in clinical studies, although these were uncommon (see section 4.8). Serum aminotransferase and total bilirubin levels should be measured prior to starting treatment, every two weeks for the first</p><p>three months of treatment, and monthly thereafter. When starting the lower strength dose (two tablets) after dose interruption, liver function should be monitored every two weeks for six weeks due to risk of increased abiraterone exposure (see section 5.2), before resuming regular monitoring. If clinical symptoms or signs suggestive of hepatotoxicity develop, serum transaminases should be measured immediately. Development of elevated aminotransferases in patients treated with Akeega should be promptly managed with treatment interruption. If at any time the ALT or AST rises above 5 times the ULN, treatment with Akeega should be interrupted and liver function closely monitored. Re-treatment</p><p>&nbsp;</p><p>may take place only after return of liver function tests to the patient&rsquo;s baseline and at a reduced dose level (see section 4.2).</p><p>&nbsp;</p><p>Treatment should be permanently discontinued in patients with elevations of ALT or AST</p><p>&gt; 20 &Iacute; ULN. Treatment should be permanently discontinued in patients who develop a concurrent elevation of ALT &gt; 3 &Iacute; ULN and a total bilirubin &gt; 2 &Iacute; ULN in the absence of biliary obstruction or other causes responsible for the concurrent elevation.</p><p>&nbsp;</p><p>If patients develop severe hepatotoxicity (ALT or AST 20 times the ULN) anytime while on therapy, treatment with Akeega should be permanently discontinued.</p><p>&nbsp;</p><p>Patients with active or symptomatic viral hepatitis were excluded from clinical studies; thus, there are no data to support the use of Akeega in this population.</p><p>&nbsp;</p><p>Moderate hepatic impairment (Child-Pugh Class B or any AST and TB &gt; 1.5 x - 3 x ULN) has been shown to increase the systemic exposure to abiraterone and niraparib (see section 5.2). There are no data on the clinical safety and efficacy of multiple doses of Akeega when administered to patients with moderate or severe hepatic impairment. The use of Akeega should be cautiously assessed in patients with moderate hepatic impairment, in whom the benefit clearly should outweigh the possible risk (see sections 4.2 and 5.2). Akeega should not be used in patients with severe hepatic impairment (see sections 4.2, 4.3 and 5.2).</p><p>&nbsp;</p><p><u>Hypoglycaemia</u></p><p>Cases of hypoglycaemia have been reported when abiraterone acetate (a component of Akeega) plus prednisone or prednisolone was administered to patients with pre-existing diabetes receiving pioglitazone or repaglinide (metabolised by CYP2C8) (see section 4.5). Blood sugar should, therefore, be monitored in patients with diabetes.</p><p>&nbsp;</p><p><u>Myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML)</u></p><p>MDS/AML, including cases with fatal outcome, have been reported in ovarian cancer studies among patients who received 300 mg of niraparib (a component of Akeega).</p><p>&nbsp;</p><p>No cases of MDS/AML have been observed in patients treated with 200 mg of niraparib and 1 000 mg of abiraterone acetate plus prednisone or prednisolone.</p><p>&nbsp;</p><p>For suspected MDS/AML or prolonged haematological toxicities that has not resolved with treatment interruption or dose reduction, the patient should be referred to a haematologist for further evaluation. If MDS and/or AML is confirmed, treatment with Akeega should be permanently discontinued, and the patient should be treated appropriately.</p><p>&nbsp;</p><p><u>Corticosteroid withdrawal and coverage of stress situations</u></p><p>Caution is advised and monitoring for adrenocortical insufficiency should occur if patients are withdrawn from prednisone or prednisolone. If Akeega is continued after corticosteroids are withdrawn, patients should be monitored for symptoms of mineralocorticoid excess (see information above).</p><p>&nbsp;</p><p>In patients on prednisone or prednisolone who are subjected to unusual stress, an increased dose of corticosteroids may be indicated before, during and after the stressful situation.</p><p>&nbsp;</p><p><u>Bone density</u></p><p>Decreased bone density may occur in men with metastatic advanced prostate cancer. The use of abiraterone acetate (a component of Akeega) in combination with a glucocorticoid could increase this effect.</p><p>&nbsp;</p><p><u>Increased fractures and mortality in combination with Radium (Ra) 223 Dichloride</u></p><p>Treatment with Akeega plus prednisone or prednisolone in combination with Ra-223 treatment is contraindicated (see section 4.3) due to an increased risk of fractures and a trend for increased</p><p>&nbsp;</p><p>mortality among asymptomatic or mildly symptomatic prostate cancer patients as observed in clinical studies with abiraterone acetate, a component of Akeega.</p><p>&nbsp;</p><p>It is recommended that subsequent treatment with Ra-223 not be initiated for at least five days after the last administration of Akeega in combination with prednisone or prednisolone.</p><p>&nbsp;</p><p><u>Hyperglycaemia</u></p><p>The use of glucocorticoids could increase hyperglycaemia, therefore blood sugar should be measured frequently in patients with diabetes.</p><p>&nbsp;</p><p><u>Skeletal muscle effects</u></p><p>Cases of myopathy and rhabdomyolysis have not been seen in patients treated with Akeega. In abiraterone acetate (a component of Akeega) monotherapy studies, most cases developed within the first six months of treatment and recovered after abiraterone acetate withdrawal. Caution is recommended in patients concomitantly treated with medicinal products known to be associated with myopathy/rhabdomyolysis.</p><p>&nbsp;</p><p><u>Interactions with other medicinal products</u></p><p>Strong inducers of CYP3A4 during treatment are to be avoided unless there is no therapeutic alternative, due to risk of decreased exposure of abiraterone (see section 4.5).</p><p>&nbsp;</p><p><u>Lactose and sodium</u></p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicinal product.</p><p>&nbsp;</p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially &lsquo;sodium-free&rsquo;.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pharmacokinetic interactions</u></p><p>No clinical study evaluating drug interactions has been performed using Akeega. Interactions that have been identified in studies with individual components of Akeega (niraparib or abiraterone acetate) determine the interactions that may occur with Akeega.</p><p>&nbsp;</p><p><em>Effects of other medicinal products on niraparib or abiraterone acetate <u>CYP3A4 inducers and inhibitors</u></em></p><p>Abiraterone is a CYP3A4 substrate. In a clinical study in healthy subjects pretreated with the strong CYP3A4 inducer rifampicin, 600 mg daily for six days, followed by a single dose of abiraterone acetate 1 000 mg, the mean plasma AUC&infin; of abiraterone was decreased by 55%. Strong inducers of CYP3A4 (e.g., phenytoin, carbamazepine, rifampicin, rifabutin, rifapentine, phenobarbital, St. John&rsquo;s wort [<em>Hypericum perforatum</em>]) during treatment with Akeega should be avoided unless there is no therapeutic alternative (see section 4.4).</p><p>&nbsp;</p><p>In a separate clinical study in healthy subjects, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone.</p><p>&nbsp;</p><p><em>Effects of niraparib or abiraterone acetate on other medicinal products <u>CYP2D6 substrates</u></em></p><p>Abiraterone is an inhibitor of CYP2D6. In a clinical study to determine the effects of abiraterone acetate plus prednisone (AAP) on a single dose of the CYP2D6 substrate dextromethorphan, the systemic exposure (AUC) of dextromethorphan was increased approximately 2.9-fold. The AUC24 for dextrorphan, the active metabolite of dextromethorphan, increased approximately 33%. Dose reduction of medicinal products with a narrow therapeutic index that are metabolised by CYP2D6 should be considered. Examples of medicinal products metabolised by CYP2D6 include metoprolol,</p><p>&nbsp;</p><p>propranolol, desipramine, venlafaxine, haloperidol, risperidone, propafenone, flecainide, codeine, oxycodone and tramadol.</p><p>&nbsp;</p><p><em><u>CYP2C8 substrates</u></em></p><p>Abiraterone is an inhibitor of CYP2C8. In a clinical study in healthy subjects, the AUC of pioglitazone, a CYP2C8 substrate, was increased by 46% and the AUCs for M-III and M-IV, the active metabolites of pioglitazone, each decreased by 10% when pioglitazone was given together with a single dose of 1 000 mg abiraterone acetate. Patients should be monitored for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with Akeega because of the abiraterone acetate component. Examples of medicinal products metabolised by CYP2C8 include pioglitazone and repaglinide (see section 4.4).</p><p>&nbsp;</p><p><u>Pharmacodynamic interactions</u></p><p>Akeega with vaccines or immunosuppressant agents has not been studied.</p><p>The data on niraparib, in combination with cytotoxic medicinal products, are limited. Caution should be taken if Akeega is used in combination with live or live-attenuated vaccines, immunosuppressant agents or with other cytotoxic medicinal products.</p><p>&nbsp;</p><p><em>Use with products known to prolong QT interval</em></p><p>Since androgen deprivation treatment may prolong the QT interval, caution is advised when administering Akeega with medicinal products known to prolong the QT interval or medicinal products able to induce torsades de pointes, such as class IA (e.g., quinidine, disopyramide) or class III (e.g., amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics, etc.</p><p>&nbsp;</p><p><em>Use with spironolactone</em></p><p>Spironolactone binds to the androgen receptor and may increase prostate specific antigen (PSA) levels. Use with Akeega is not recommended (see section 5.1).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential/Contraception in males and females</u></p><p>It is not known whether components of Akeega or their metabolites are present in semen.</p><p>&nbsp;</p><p>During treatment and for four months after the last dose of Akeega:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A condom is required if the patient is engaged in sexual activity with a pregnant woman.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If the patient is engaged in sex with a woman of childbearing potential, a condom is required along with another effective contraceptive method.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Akeega is not for use in women (see section 4.3).</p><p>&nbsp;</p><p>There are no data from the use of Akeega in pregnant women. Akeega has the potential to cause foetal harm based on the mechanism of action of both components and findings from animal studies with abiraterone acetate. Animal developmental and reproductive toxicology studies were not conducted with niraparib (see section 5.3).</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>Akeega is not for use in women.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>There are no clinical data on fertility with Akeega. In animal studies, male fertility was reduced with niraparib or abiraterone acetate but these effects were reversible following treatment cessation (see section 5.3)<em>.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Akeega has moderate influence on the ability to drive or use machines. Patients who take Akeega may experience asthenia, fatigue, dizziness or difficulties concentrating. Patients should use caution when driving or using machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The overall safety profile of Akeega is based on data from a Phase 3, randomised, double-blind, placebo-controlled study, MAGNITUDE cohort 1 (N=212). The most common adverse reactions of all grades occurring in &gt;10% in the niraparib plus AAP arm were anaemia (50.0%), hypertension (33.0%), constipation (33.0%), fatigue (29.7%), nausea (24.5%), thrombocytopenia (23.1%), dyspnoea</p><p>(17.9%), back pain (17.0%), decreased appetite (15.6%), neutropenia (15.1%), arthralgia (15.1%),</p><p>vomiting (14.6%), hypokalaemia (13.7%), dizziness (12.7%), insomnia (11.3%), hyperglycaemia (11.8%) and urinary tract infection (10.4%). The most frequently observed Grade 3-4 adverse reactions were anaemia (30.2%), hypertension (15.6%), thrombocytopenia (7.5%), neutropenia (6.6%) and blood alkaline phosphatase increased (5.7%).</p><p>&nbsp;</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions observed during clinical studies are listed below by frequency category. Frequency categories are defined as follows: very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1 000 to &lt; 1/100); rare (&ge; 1/10 000 to &lt; 1/1 000); very rare (&lt; 1/10 000); and not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><p>&nbsp;</p><p>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions identified in clinical studies</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Infections and infestations</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>urinary tract infection</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>pneumoniae, bronchitis, nasopharyngitis</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>urosepsis, conjunctivitis</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Blood and lymphatic system disorders</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>anaemia, thrombocytopenia, neutropenia, leukopenia</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>lymphopenia</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>pancytopenia<sup>7</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>hypersensitivity (including anaphylaxis)<sup>7</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>decreased appetite, hypokalaemia</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>hypertriglyceridaemia</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Psychiatric disorders</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>insomnia</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>depression, anxiety</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>confusional state, cognitive impairment<sup>8</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Nervous system disorders</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>dizziness</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>headache</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>dysgeusia</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>posterior reversible encephalopathy syndrome (PRES)<sup>7</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Cardiac disorders</strong></p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>tachycardia, palpitations, atrial fibrillation, cardiac failure<sup>1</sup>, myocardial infarction</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>angina pectoris<sup>2</sup>, QT prolongation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Vascular disorders</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>hypertension</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>hypertensive crisis<sup>7</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Endocrine disorders</strong></p></td><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>adrenal insufficiency<sup>9</sup></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>dyspnoea</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>cough, pulmonary embolism, pneumonitis</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>epistaxis</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>allergic alveolitis<sup>9</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>constipation, nausea, vomiting</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table 3:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adverse reactions identified in clinical studies</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>abdominal pain<sup>3</sup>, dyspepsia, diarrhoea, abdominal distention, stomatitis, dry mouth</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>mucosal inflammation</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Hepatobiliary disorders</strong></p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>hepatitis<sup>4</sup></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>acute hepatic failure</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>rash<sup>5</sup></p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>photosensitivity</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>back pain, arthralgia</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>myalgia</p></td></tr><tr><td style="vertical-align:top"><p>not known</p></td><td style="vertical-align:top"><p>myopathy<sup>9</sup>, rhabdomyolysis<sup>9</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>haematuria</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>General disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>fatigue, asthenia</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>oedema peripheral</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>blood alkaline phosphatase increased, weight decreased</p></td></tr><tr><td style="vertical-align:top"><p>common</p></td><td style="vertical-align:top"><p>blood creatinine increased, AST increased, ALT increased</p></td></tr><tr><td style="vertical-align:top"><p>uncommon</p></td><td style="vertical-align:top"><p>gamma-glutamyl transferase increased</p></td></tr><tr><td style="vertical-align:top"><p><strong>Injury, poisoning and procedural complications</strong></p></td><td style="vertical-align:top"><p>very common</p></td><td style="vertical-align:top"><p>fractures<sup>6</sup></p></td></tr></tbody></table><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[if gte vml 1]><v:rect
 id="Rectangle_x0020_114" o:spid="_x0000_s1026" style='position:absolute;
 left:0;text-align:left;margin-left:461.9pt;margin-top:-71.65pt;width:2.65pt;
 height:.5pt;z-index:-17411072;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:page;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:page;mso-height-relative:page;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="black" stroked="f">
 <w:wrap anchorx="page"/>
</v:rect><![endif]--><img width="4" height="1" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" />Includes cardiac failure congestive, cor pulmonale, left ventricular dysfunction</p><p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes coronary artery disease, acute coronary syndrome</p><p>3&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes abdominal pain upper</p><p>4&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes hepatitis acute, fulminant, hepatic cytolysis, hepatotoxicity</p><p>5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes rash, erythema, dermatitis, rash maculo-papular, rash pruritic</p><p>6&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Includes osteoporosis and osteoporosis-related fractures</p><p>7&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not observed with Akeega. Reported in post-marketing experience with niraparib monotherapy</p><p>8&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not observed with Akeega. Reported with niraparib monotherapy</p><p>9&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Not observed with Akeega. Reported in post-marketing experience with abiraterone monotherapy</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><em>Haematological toxicities</em></p><p>Haematological toxicities (anaemia, thrombocytopenia and neutropenia) including laboratory findings are the most frequent adverse reactions attributable to niraparib (a component of Akeega). These toxicities generally occurred within the first two months of treatment with the incidence decreasing over time.</p><p>&nbsp;</p><p>In the MAGNITUDE study and other Akeega studies, the following haematological parameters were inclusion criteria: absolute neutrophil count (ANC) &ge; 1 500 cells/&mu;L; platelets &ge; 100 000 cells/&mu;L and haemoglobin &ge; 9 g/dL. Haematological adverse reactions were managed with laboratory monitoring and dose modifications (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p><em>Anaemia</em></p><p>Anaemia was the most frequent adverse reaction (50.0%) and most commonly observed Grade 3-4 event (30.2%) in the MAGNITUDE study. Anaemia occurred early during the course of therapy (median time to onset of 59 days). In the MAGNITUDE study, dose interruptions occurred in 22.6% and dose reductions in 13.7% of patients. Twenty-seven percent of patients received at least one anaemia-related transfusion. Anaemia caused discontinuation in a relatively small number of patients (2.4%).</p><p>&nbsp;</p><p><em>Thrombocytopenia</em></p><p>In the MAGNITUDE study, 23.1% of treated patients reported thrombocytopenia while 7.5% of patients experienced Grade 3-4 thrombocytopenia. Median time from first dose to first onset was 56 days. In the MAGNITUDE study, thrombocytopenia was managed with dose modification (interruption 10.8% and reduction in 2.8%) and platelet transfusion (2.4%) where appropriate (see</p><p>&nbsp;</p><p>section 4.2). Discontinuation occurred in 0.5% of patients. In the MAGNITUDE study, 1.4% of patients experienced a nonlife-threatening bleeding event.</p><p>&nbsp;</p><p><em>Neutropenia</em></p><p>In the MAGNITUDE study, 15.1% of patients experienced neutropenia with Grade 3-4 neutropenia reported in 6.6% of patients. Median time from first dose to first report of neutropenia was 54 days. Neutropenia led to treatment interruption in 6.6% of patients and dose reduction in 1.4%. There were no treatment discontinuations due to neutropenia. In the MAGNITUDE study, 0.9% of patients had a concurrent infection.</p><p>&nbsp;</p><p><em>Hypertension</em></p><p>Hypertension is an adverse reaction for both components of Akeega and patients with uncontrolled hypertension (persistent systolic blood pressure [BP] &ge;160 mmHg or diastolic BP &ge;100 mmHg) were excluded in all combination studies. Hypertension was reported in 33% of patients of whom 15.6% had Grade &ge; 3. The median time to onset of hypertension was 60.5 days. Hypertension was managed with adjunctive medicinal products.</p><p>&nbsp;</p><p>Patients should have blood pressure controlled before initiating Akeega and blood pressure should be monitored on treatment (see section 4.4).</p><p>&nbsp;</p><p><em>Cardiac events</em></p><p>In the MAGNITUDE study, the incidence of TEAEs of cardiac disorder (all grades) was similar in both arms, except for the arrhythmia category, where AEs were observed in 13.7% of patients in the niraparib plus AAP arm and 7.6% of patients in the placebo plus AAP arm (see section 4.4). Higher frequency of arrhythmias was largely due to low grade events of palpitations, tachycardias and atrial arrhythmias.</p><p>&nbsp;</p><p>The median time to onset of the events of arrhythmias was 105 days in the niraparib plus AAP arm and 262 days in the placebo plus AAP arm. Events of arrhythmia were resolved in 62% of patients in the niraparib plus AAP arm and 63% of subjects in the placebo plus AAP arm.</p><p>&nbsp;</p><p>The incidence of cardiac failure, cardiac failure acute, cardiac failure chronic, cardiac failure congestive was 2.4% in the niraparib plus AAP arm vs 1.9% in placebo plus AAP arm. The median time to onset of the AESI of cardiac failure was 206 days in the niraparib plus AAP arm and 83 days in the placebo plus AAP arm. Events of cardiac failure were resolved in 20% of patients the niraparib plus AAP arm and 25% of patients in the placebo plus AAP arm.</p><p>&nbsp;</p><p>The grouped term of ischemic heart disease (included preferred terms of angina pectoris, acute myocardial infarction, acute coronary syndrome, unstable angina, and arteriosclerosis coronary artery) occurred in 4.2% of the niraparib plus AAP arm vs 4.3% in the placebo plus AAP arm. The median time to onset of the AESI of ischemic heart disease was 538 days in the niraparib plus AAP arm and 257 days in the placebo plus AAP arm. Events of ischemic heart disease were resolved in 78% of patients in both arms.</p><p>&nbsp;</p><p><em>Hepatotoxicity</em></p><p>The overall incidence of hepatotoxicity in the MAGNITUDE study was similar for the niraparib plus AAP (12.7%) and placebo plus AAP (12.8%) arms (see sections 4.2 and 4.4). The majority of these events were low grade aminotransferase elevations. Grade 3 events occurred in 1.4% of patients and a Grade 4 event occurred in only one patient (0.5%). The incidence of SAEs was also 0.9%. The median time to onset of hepatotoxicity in the MAGNITUDE study was 34 days. Hepatotoxicity was managed with dose interruptions in 0.9% and dose reduction in 0.5% of patients. In the MAGNITUDE study, 0.5% of patients discontinued treatment due to hepatotoxicity.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>No studies have been conducted in paediatric patients with Akeega.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p>&nbsp;</p><p><u>To report any side effects:</u></p><p>&nbsp;</p><p><strong>Saudi Arabia:</strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p><em>&nbsp;</em></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><strong>Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific treatment in the event of Akeega overdose. In the event of an overdose, physicians should follow general supportive measures and should treat patients symptomatically, including monitoring for arrhythmias, hypokalaemia and signs and symptoms of fluid retention. Liver function also should be assessed.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: antineoplastic agents, other antineoplastic agents, ATC code: L01XK <u>Mechanism of action</u></p><p>Akeega is a combination of niraparib, an inhibitor of poly(ADP-ribose) polymerase (PARP), and abiraterone acetate (a prodrug of abiraterone), a CYP17 inhibitor targeting two oncogenic dependencies in patients with mCRPC and HRR gene mutations.</p><p>&nbsp;</p><p><em>Niraparib</em></p><p>Niraparib is an inhibitor of poly(ADP-ribose) polymerase (PARP) enzymes, PARP-1 and PARP-2, which play a role in DNA repair. <em>In vitro </em>studies have shown that niraparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes, resulting in DNA damage, apoptosis and cell death.</p><p>&nbsp;</p><p><em>Abiraterone acetate</em></p><p>Abiraterone acetate is converted <em>in vivo </em>to abiraterone, an androgen biosynthesis inhibitor. Specifically, abiraterone selectively inhibits the enzyme 17&alpha;-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed in, and is required for, androgen biosynthesis in testicular, adrenal and prostatic tumour tissues. CYP17 catalyses the conversion of pregnenolone and progesterone into testosterone precursors, DHEA and androstenedione, respectively, by 17&alpha;-hydroxylation and cleavage of the C17,20 bond. CYP17 inhibition also results in increased mineralocorticoid production by the adrenals (see section 4.4).</p><p>&nbsp;</p><p>Androgen-sensitive prostatic carcinoma responds to treatment that decreases androgen levels. Androgen deprivation therapies, such as treatment with luteinising hormone releasing hormone (LHRH) analogues or orchiectomy, decrease androgen production in the testes but do not affect androgen production by the adrenals or in the tumour. Treatment with abiraterone decreases serum testosterone to undetectable levels (using commercial assays) when given with LHRH analogues (or orchiectomy).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em>Abiraterone acetate</em></p><p>Abiraterone decreases serum testosterone and other androgens to levels lower than those achieved by the use of LHRH analogues alone or by orchiectomy. This results from the selective inhibition of the CYP17 enzyme required for androgen biosynthesis.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><em>First-line treatment of mCRPC patients with BRCA 1/2 mutations</em></p><p>The efficacy of Akeega was established in a randomised placebo-controlled multicentre Phase 3 clinical study of patients with mCRPC, MAGNITUDE (Study 64091742PCR3001).</p><p>&nbsp;</p><p>MAGNITUDE was a Phase 3, randomised, double-blind, placebo-controlled, multicentre study that evaluated treatment with the combination of niraparib (200 mg) and abiraterone acetate (1 000 mg) plus prednisone (10 mg) daily versus AAP standard of care. Efficacy data are based on Cohort 1 that consisted of 423 patients with mCRPC and select HRR gene mutations, who were randomised (1:1) to receive either niraparib plus AAP (N=212) or placebo plus AAP (N=211) orally daily. Treatment was continued until disease progression, unacceptable toxicity, or death.</p><p>&nbsp;</p><p>Patients with mCRPC who had not received prior systemic therapy in the mCRPC setting except for a short duration of prior AAP (up to 4 months) and ongoing ADT, were eligible. Plasma, blood, and/or tumour tissue samples for all patients were tested by validated next generation sequencing tests to determine germline and/or somatic HRR gene mutation status. There were 225 subjects with a BRCA1/2 mutation enrolled in the study (113 received Akeega). There were an additional 198 patients with a non-BRCA1/2 mutation (ATM, CHEK2, CDK12, PALB2, FANCA, BRIP1, HDAC2) enrolled in the study (99 received Akeega).</p><p>&nbsp;</p><p>The primary endpoint was radiographic progression free survival (rPFS) as determined by blinded independent central radiology (BICR) review based on Response Evaluation Criteria In Solid Tumours (RECIST) 1.1 (soft and tissue lesions) and Prostate Cancer Working Group-3 (PCWG-3) criteria (bone lesions). Time to symptomatic progression (TSP), time to cytotoxic chemotherapy (TCC), and overall survival (OS) were included as secondary efficacy endpoints.</p><p>&nbsp;</p><p>In the All HRR Population, the primary efficacy results with a median follow-up of 18.6 months showed statistically significant improvement in BICR-assessed rPFS with a HR =0.729 (95% CI: 0.556, 0.956; p=0.0217).</p><p>&nbsp;</p><p>Table 4 summarises the demographics and baseline characteristics of BRCA patients enrolled in Cohort 1 of the MAGNITUDE study. The median PSA at diagnosis was 41.07 ug/L (range 01-12080). All patients had an Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0 or 1 at study entry. All patients who had not received prior orchiectomy continued background androgen deprivation therapy with a GnRH analogue.</p><p>&nbsp;</p><p>Table 4:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Summary of demographics and baseline characteristics in the MAGNITUDE study Cohort 1 (BRCA)</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>Total N=225</strong></p><p><strong>n (%)</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Age (years)</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 65</p></td><td style="vertical-align:top"><p>76 (33.8)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 65-74</p></td><td style="vertical-align:top"><p>96 (42.7)</p></td></tr><tr><td style="vertical-align:top"><p>&ge; 75</p></td><td style="vertical-align:top"><p>53 (23.6)</p></td></tr><tr><td style="vertical-align:top"><p>Median</p></td><td style="vertical-align:top"><p>68.0</p></td></tr><tr><td style="vertical-align:top"><p>Range</p></td><td style="vertical-align:top"><p>43-100</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Race</strong></p></td></tr><tr><td style="vertical-align:top"><p>Caucasian</p></td><td style="vertical-align:top"><p>162 (72.0)</p></td></tr><tr><td style="vertical-align:top"><p>Asian</p></td><td style="vertical-align:top"><p>38 (16.9)</p></td></tr><tr><td style="vertical-align:top"><p>Black</p></td><td style="vertical-align:top"><p>3 (1.3)</p></td></tr><tr><td style="vertical-align:top"><p>Unknown</p></td><td style="vertical-align:top"><p>22 (9.8)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Stratification factors</strong></p></td></tr><tr><td style="vertical-align:top"><p>Past taxane-based chemotherapy exposure</p></td><td style="vertical-align:top"><p>55 (24.4)</p></td></tr><tr><td style="vertical-align:top"><p>Past AR-targeted therapy exposure</p></td><td style="vertical-align:top"><p>11 (4.9)</p></td></tr><tr><td style="vertical-align:top"><p>Prior AAP use</p></td><td style="vertical-align:top"><p>59 (26.2)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p><strong>Baseline disease characteristics</strong></p></td></tr><tr><td style="vertical-align:top"><p>Gleason score &ge; 8</p></td><td style="vertical-align:top"><p>155 (69.2)</p></td></tr><tr><td style="vertical-align:top"><p>Bone involvement</p></td><td style="vertical-align:top"><p>192 (85.3)</p></td></tr><tr><td style="vertical-align:top"><p>Visceral disease (liver, lung, adrenal gland, other)</p></td><td style="vertical-align:top"><p>48 (21.3)</p></td></tr><tr><td style="vertical-align:top"><p>Metastasis stage at initial diagnosis (M1)</p></td><td style="vertical-align:top"><p>120 (53.3)</p></td></tr><tr><td style="vertical-align:top"><p>Median time from initial diagnosis to randomization (years)</p></td><td style="vertical-align:top"><p>2.26</p></td></tr><tr><td style="vertical-align:top"><p>Median time from mCRPC to first dose (years)</p></td><td style="vertical-align:top"><p>0.27</p></td></tr><tr><td style="vertical-align:top"><p>BPI-SF pain score at baseline (last score before first dose)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>0</p></td><td style="vertical-align:top"><p>114 (50.7)</p></td></tr><tr><td style="vertical-align:top"><p>1 to 3</p></td><td style="vertical-align:top"><p>91 (40.4)</p></td></tr><tr><td style="vertical-align:top"><p>&gt; 3</p></td><td style="vertical-align:top"><p>20 (8.9)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>A statistically significant improvement in BICR-assessed rPFS was observed in the primary analysis for BRCA subjects treated with niraparib plus AAP, compared with BRCA subjects treated with placebo plus AAP. Key efficacy results in the BRCA population are presented in Table 5. The Kaplan- Meier curves for BICR assessed rPFS in the BRCA population are shown in Figure 1.</p><p>&nbsp;</p><p>&nbsp;</p><p>Table 5:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Efficacy results from the BRCA population of the MAGNITUDE study</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Endpoints</strong></p></td><td style="vertical-align:top"><p><strong>Akeega (N=113)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo (N=112)</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Radiographic Progression-free Survival<sup>1</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Event of disease progression or death (%)</p></td><td style="vertical-align:top"><p>45 (39.8%)</p></td><td style="vertical-align:top"><p>64 (57.1%)</p></td></tr><tr><td style="vertical-align:top"><p>Median, months (95% CI)</p></td><td style="vertical-align:top"><p>16.6 (13.9, NE)</p></td><td style="vertical-align:top"><p>10.9 (8.3, 13.8)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.533 (0.361, 0.789)</p></td></tr><tr><td style="vertical-align:top"><p>p-value</p></td><td colspan="2" style="vertical-align:top"><p>0.0014</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>Overall Survival<sup>2</sup></strong></p></td></tr><tr><td style="vertical-align:top"><p>Hazard Ratio (95% CI)</p></td><td colspan="2" style="vertical-align:top"><p>0.881 (0.582, 1.335)</p></td></tr></tbody></table><p>1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary analysis/Interim analysis (data cut-off: 08OCT2021), with 18.6 months median follow-up</p><p>2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Interim analysis 2 (data cut-off: 17JUN2022), with 26.8 months median follow-up NE = Not estimable</p><p>&nbsp;</p><p><strong>Figure 1:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Kaplan-Meier Plot of BICR assessed radiologic progression-free survival in the BRCA population (MAGNITUDE, primary analysis)</strong></p><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
  path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
  <v:stroke joinstyle="miter"/>
  <v:formulas>
   <v:f eqn="if lineDrawn pixelLineWidth 0"/>
   <v:f eqn="sum @0 1 0"/>
   <v:f eqn="sum 0 0 @1"/>
   <v:f eqn="prod @2 1 2"/>
   <v:f eqn="prod @3 21600 pixelWidth"/>
   <v:f eqn="prod @3 21600 pixelHeight"/>
   <v:f eqn="sum @0 0 1"/>
   <v:f eqn="prod @6 1 2"/>
   <v:f eqn="prod @7 21600 pixelWidth"/>
   <v:f eqn="sum @8 21600 0"/>
   <v:f eqn="prod @7 21600 pixelHeight"/>
   <v:f eqn="sum @10 21600 0"/>
  </v:formulas>
  <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
  <o:lock v:ext="edit" aspectratio="t"/>
 </v:shapetype><v:shape id="image1.png" o:spid="_x0000_s1026" type="#_x0000_t75"
  style='position:absolute;margin-left:70.55pt;margin-top:9.85pt;width:424.8pt;
  height:295.2pt;z-index:2;visibility:visible;mso-wrap-style:square;
  mso-wrap-distance-left:0;mso-wrap-distance-top:0;mso-wrap-distance-right:0;
  mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
  mso-position-horizontal-relative:page;mso-position-vertical:absolute;
  mso-position-vertical-relative:text'>
  <v:imagedata src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
   o:title=""/>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="566" height="394" alt="" vspace="0" hspace="0" border="0" style="width:566px;height:394px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" src="file:///C:/Users/RAljasmi/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Akeega in all subsets of the paediatric population in prostate malignant neoplasms. See section 4.2 for information on paediatric use.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Co-administration of niraparib and abiraterone has no impact on the exposures of the individual moeities. The AUC and Cmax are comparable for niraparib and abiraterone when administered as Akeega regular strength (100 mg/500 mg) film-coated tablet or as combination of individual components when compared to respective monotherapy exposures.</p><p><u>Absorption</u></p><p><em>Akeega</em></p><p>In mCRPC patients, under fasted and modified fasted conditions, upon administration of multiple doses of Akeega tablets, the maximum plasma concentration was achieved within a median of 3 hours for niraparib, and a median of 1.5 hours for abiraterone.</p><p>&nbsp;</p><p>In a relative bioavailability study, the maximum (Cmax) and total (AUC0-72h) exposure of abiraterone in mCRPC patients (n=67) treated with Akeega lower strength film-coated tablets (2 x 50 mg/500 mg) was 33% and 22% higher, respectively, when compared to exposures in patients (n=67) taking individual single agents (100 mg niraparib capsule and 4 x 250 mg abiraterone acetate tablets) (see section 4.2). The inter-subject variability (%CV) in exposures were 80.4% and 72.9%, respectively.</p><p>Niraparib exposure was comparable between Akeega lower strength film-coated tablets and single agents.</p><p>&nbsp;</p><p><em>Niraparib</em></p><p>The absolute bioavailability of niraparib is approximately 73%. Niraparib is a substrate of P- glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP). However, due to its high</p><p>&nbsp;</p><p>permeability and bioavailability, the risk of clinically relevant interactions with medicinal products that inhibit these transporters is unlikely.</p><p>&nbsp;</p><p><em>Abiraterone acetate</em></p><p>Abiraterone acetate is rapidly converted in vivo to abiraterone (see section 5.1).</p><p>&nbsp;</p><p>Administration of abiraterone acetate with food, compared with administration in a fasted state, results in up to a 10-fold (AUC) and up to a 17-fold (Cmax) increase in mean systemic exposure of abiraterone, depending on the fat content of the meal. Given the normal variation in the content and composition of meals, taking abiraterone acetate with meals has the potential to result in highly variable exposures.</p><p>Therefore, abiraterone acetate must not be taken with food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>Based on population pharmacokinetic analysis, the apparent volume of distribution of niraparib and abiraterone were 1,117 L and 25,774 L, respectively, indicative of extensive extravascular distribution<em>.</em></p><p><em>&nbsp;</em></p><p><em>Niraparib</em></p><p>Niraparib was moderately protein-bound in human plasma (83.0%), mainly with serum albumin.</p><p>&nbsp;</p><p><em>Abiraterone acetate</em></p><p>The plasma protein binding of <sup>14</sup>C-abiraterone in human plasma is 99.8%.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p><em>Niraparib</em></p><p>Niraparib is metabolised primarily by carboxylesterases (CEs) to form a major inactive metabolite, M1. In a mass balance study, M1 and M10 (the subsequently formed M1 glucuronides) were the major circulating metabolites. The potential to inhibit CYP3A4 at the intestinal level has not been established at relevant niraparib concentrations. Niraparib weakly induces CYP1A2 at high concentrations <em>in vitro</em>.</p><p>&nbsp;</p><p><em>Abiraterone acetate</em></p><p>Following oral administration of <sup>14</sup>C-abiraterone acetate as capsules, abiraterone acetate is hydrolysed by CEs to abiraterone, which then undergoes metabolism including sulphation, hydroxylation and oxidation primarily in the liver. Abiraterone is a substrate of CYP3A4 and sulfotransferase 2A1 (SULT2A1). The majority of circulating radioactivity (approximately 92%) is found in the form of metabolites of abiraterone. Of 15 detectable metabolites, two main metabolites, abiraterone sulphate and N-oxide abiraterone sulphate, each represents approximately 43% of total radioactivity.</p><p>Abiraterone is an inhibitor of the hepatic drug metabolising enzymes CYP2D6 and CYP2C8 (see section 4.5).</p><p>&nbsp;</p><p><u>Elimination</u></p><p><em>Akeega</em></p><p>The mean t&frac12; of niraparib and abiraterone when given in combination were approximately 62 hours and 20 hours, respectively, and apparent CL/F of niraparib and abiraterone were 16.7 L/h and 1673 L/h, respectively based on the population pharmacokinetic analysis in subjects with mCRPC.</p><p>&nbsp;</p><p><em>Niraparib</em></p><p>Niraparib is eliminated primarily through the hepatobiliary and renal routes. Following an oral administration of a single 300 mg dose of [<sup>14</sup>C]-niraparib, on average 86.2% (range 71% to 91%) of the dose was recovered in urine and faeces over 21 days. Radioactive recovery in the urine accounted for 47.5% (range 33.4% to 60.2%) and in the faeces for 38.8% (range 28.3% to 47.0%) of the dose. In pooled samples collected over six days, 40.0% of the dose was recovered in the urine primarily as metabolites and 31.6% of the dose was recovered in the faeces primarily as unchanged niraparib. The metabolite M1 is a substrate of Multidrug And Toxin Extrusion (MATE) 1 and 2.</p><p>&nbsp;</p><p><em>Abiraterone acetate</em></p><p>Following oral administration of <sup>14</sup>C-abiraterone acetate 1 000 mg, approximately 88% of the radioactive dose is recovered in faeces and approximately 5% in urine. The major compounds present in faeces are unchanged abiraterone acetate and abiraterone (approximately 55% and 22% of the administered dose, respectively).</p><p>&nbsp;</p><p><em>Effects of niraparib or abiraterone on transporters</em></p><p>Niraparib inhibits P-gp weakly with an IC50=161 &mu;M. Niraparib is an inhibitor of BCRP, Organic Cation Transporter 1 (OCT1), MATE-1 and 2 with IC50 values of 5.8 &mu;M, 34.4 &mu;M, 0.18 &mu;M and</p><p>&le; 0.14 &mu;M, respectively. The major metabolites of abiraterone, abiraterone sulphate and N-oxide abiraterone sulphate, were shown to inhibit the hepatic uptake transporter Organic Anion Transport Polypeptide 1B1 (OATP1B1) and as a consequence, the plasma exposures of medicinal products eliminated by OATP1B1 may increase. There are no clinical data available to confirm transporter OATP1B1 based interaction.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Hepatic impairment</em></p><p>Based on the population pharmacokinetic analysis of data from clinical studies where prostate cancer patients received niraparib alone or niraparib/AA in combination, mild hepatic impairment (NCI- ODWG criteria, n=231) did not affect the exposure of niraparib.</p><p>&nbsp;</p><p>In a clinical study of cancer patients using NCI-ODWG criteria to classify the degree of hepatic impairment, niraparib AUCinf&nbsp; in patients with moderate hepatic impairment (n=8) was 1.56 (90% CI: 1.06 to 2.30) times the niraparib AUCinf in patients with normal hepatic function (n=9) following administration of a single 300 mg dose.</p><p>&nbsp;</p><p>The pharmacokinetics of abiraterone was examined in subjects with pre-existing mild (n = 8) or moderate (n = 8) hepatic impairment (Child-Pugh Class A and B, respectively) and in 8 healthy control subjects. Systemic exposure to abiraterone after a single oral 1,000 mg dose increased by approximately 1.11-fold and 3.6-fold in subjects with mild and moderate pre-existing hepatic impairment, respectively.</p><p>&nbsp;</p><p>In another study, the pharmacokinetics of abiraterone were examined in subjects with pre-existing severe (n = 8) hepatic impairment (Child-Pugh Class C) and in 8 healthy control subjects with normal hepatic function. The AUC of abiraterone increased by approximately 7-fold and the fraction of free drug increased by 1.8-fold in subjects with severe hepatic impairment compared to subjects with normal hepatic function. There is no clinical experience using Akeega in patients with moderate and severe hepatic impairment (see section 4.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>Based on the population pharmacokinetic analysis of data from clinical studies where prostate cancer patients received niraparib alone or niraparib/AA in combination, patients with mild (creatinine clearance 60-90 mL/min, n=337) and moderate (creatinine clearance 30-60 mL/min, n=114) renal impairment had mildly reduced niraparib clearance compared to individuals with normal renal function (up to 13% higher exposure in mild and 13-40% higher exposure in moderate renal impairment).</p><p>&nbsp;</p><p>The pharmacokinetics of abiraterone was compared in patients with end-stage renal disease on a stable haemodialysis schedule (n=8) versus matched control subjects with normal renal function (n=8).</p><p>Systemic exposure to abiraterone after a single oral 1,000 mg dose did not increase in subjects with end-stage renal disease on dialysis. There is no clinical experience using Akeega in patients with severe renal impairment (see section 4.2).</p><p>&nbsp;</p><p><em>Weight, age and race</em></p><p>Based on the population pharmacokinetic analysis of data from clinical studies where prostate cancer patients received niraparib or abiraterone acetate alone or in combination:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Body weight did not have a clinically meaningful influence on the exposure of niraparib (body weight range: 43.3-165 kg) and abiraterone (body weight range: 56.0-135 kg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Age had no significant impact on the pharmacokinetics of niraparib (age range 45-90 years) and abiraterone (age range 19-85 years).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; There is insufficient data to conclude on the impact of race on the pharmacokinetics of niraparib and abiraterone<em>.</em></p><p><em>&nbsp;</em></p><p><em>Paediatric population</em></p><p>No studies have been conducted to investigate the pharmacokinetics of Akeega in paediatric patients.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Akeega</u></p><p>Non-clinical studies with Akeega have not been performed. The nonclinical toxicology data are based on findings in studies with niraparib and abiraterone acetate individually.</p><p>&nbsp;</p><p><u>Niraparib</u></p><p><em>In vitro</em>, niraparib inhibited the dopamine transporter at concentration levels below human exposure levels. In mice, single doses of niraparib increased intracellular levels of dopamine and metabolites in cortex. Reduced locomotor activity was seen in one of two single dose studies in mice. The clinical relevance of these findings is not known. No effect on behavioural and/or neurological parameters have been observed in repeat-dose toxicity studies in rats and dogs at estimated CNS exposure levels similar to or below expected therapeutic exposure levels.</p><p>&nbsp;</p><p>Decreased spermatogenesis was observed in both rats and dogs at exposure levels below therapeutic exposure levels and were largely reversible within four weeks of cessation of dosing.</p><p>&nbsp;</p><p>Niraparib was not mutagenic in a bacterial reverse mutation assay (Ames) test but was clastogenic in an <em>in vitro </em>mammalian chromosomal aberration assay and in an <em>in vivo </em>rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the primary pharmacology of niraparib and indicates potential for genotoxicity in humans.</p><p>&nbsp;</p><p>Reproductive and developmental toxicity studies have not been conducted with niraparib. Carcinogenicity studies have not been conducted with niraparib.</p><p><u>Abiraterone acetate</u></p><p>In animal toxicity studies, circulating testosterone levels were significantly reduced. As a result, reduction in organ weights and morphological and/or histopathological changes in the reproductive organs, and the adrenal, pituitary and mammary glands were observed. All changes showed complete or partial reversibility. The changes in the reproductive organs and androgen-sensitive organs are consistent with the pharmacology of abiraterone. All treatment-related hormonal changes reversed or were shown to be resolving after a 4-week recovery period.</p><p>&nbsp;</p><p>In fertility studies in both male and female rats, abiraterone acetate reduced fertility, which was completely reversible in four to 16 weeks after abiraterone acetate was stopped.</p><p>&nbsp;</p><p>In a developmental toxicity study in the rat, abiraterone acetate affected pregnancy including reduced foetal weight and survival. Effects on the external genitalia were observed though abiraterone acetate was not teratogenic.</p><p>&nbsp;</p><p>In these fertility and developmental toxicity studies performed in the rat, all effects were related to the pharmacological activity of abiraterone.</p><p>&nbsp;</p><p>Aside from reproductive organ changes seen in all animal toxicology studies, non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity and carcinogenic potential. Abiraterone acetate was not carcinogenic in a</p><p>6-month study in the transgenic (Tg.rasH2) mouse. In a 24-month carcinogenicity study in the rat, abiraterone acetate increased the incidence of interstitial cell neoplasms in the testes. This finding is considered related to the pharmacological action of abiraterone and rat-specific. Abiraterone acetate was not carcinogenic in female rats.</p><p>&nbsp;</p><p><u>Environmental risk assessment (ERA)</u></p><p>The active substance, abiraterone, shows an environmental risk for the aquatic environment, especially to fish (see section 6.6).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Akeega 50 mg/500 mg film-coated tablets</u></p><p><em>Tablet core</em></p><p>Colloidal anhydrous silica Crospovidone Hypromellose</p><p>Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium lauryl sulfate</p><p>&nbsp;</p><p><em>Film-coating</em></p><p>Iron oxide black (E172) Iron oxide red (E172) Iron oxide yellow (E172) Sodium lauryl sulphate</p><p>Glycerol monocaprylocaprate Polyvinyl alcohol</p><p>Talc</p><p>Titanium dioxide (E171)</p><p>&nbsp;</p><p><u>Akeega 100 mg/500 mg film-coated tablets</u></p><p><em>Tablet core</em></p><p>Colloidal anhydrous silica Crospovidone Hypromellose</p><p>Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium lauryl sulfate</p><p>&nbsp;</p><p><em>Film-coating</em></p><p>Iron oxide red (E172) Iron oxide yellow (E172) Sodium lauryl sulphate</p><p>Glycerol monocaprylocaprate Polyvinyl alcohol</p><p>Talc</p><p>Titanium dioxide (E171)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                30 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each 28-day carton contains 56 film-coated tablets in two cardboard wallet packs each containing 28 film-coated tablets in a PVdC/PE/PVC blister with an aluminum push-through foil.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Based on its mechanism of action, this medicinal product may harm a developing foetus. Therefore, women who are or may become pregnant should handle Akeega with protection, e.g., gloves (see section 4.6).</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements. This medicinal product may pose a risk to the aquatic environment (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Janssen-Cilag International NV Turnhoutseweg 30
B-2340 Beerse Belgium


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                19 April 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>